Researchers Optimistic After Dose-Determining Trial of Compound Against Metastatic Castration-Resistant Prostate Cancer

Joshi Alumkal, MD finds good tolerability and encouraging efficacy data for the pan-BET bromodomain inhibitor in combination with enzalutamide.